Fibrinolytic therapy restores blood flow in patients experiencing an ST-elevation myocardial infarction (STEMI), a severe heart attack caused by a blocked coronary artery. Despite the effectiveness of fibrinolysis, intracranial hemorrhage (ICH), or bleeding within the brain, remains a rare but serious complication, described as its “Achilles heel.” While tenecteplase (TNK) is a widely used fibrinolytic drug known for its targeted action and ease of single-dose IV administration, predicting which patients are at the highest risk of ICH has remained a clinical challenge.
In a recent European Heart Journal study, the CVC’s Drs. Paul Armstrong and Cindy Westerhout, together with Dr. Thierry Danays, analyzed pooled data from 15,954 patients across six global clinical trials in which CVC has been involved over the 25 years from 1997 – 2022. The authors investigated key risk factors associated with 30-day ICH following weight-adjusted TNK therapy.
Statistical modeling identified five primary risk factors: age, female sex, lower body weight, systolic blood pressure, and total TNK dose. While age, sex, and weight were key non-modifiable predictors (female sex carried a 49% higher risk, and every 5 kg lower weight increased risk by 16%), the study highlighted two critical modifiable factors clinicians can potentially manage:
- Systolic Blood Pressure: Bleeding risk began rising above a systolic blood pressure of 110 mmHg (about a 2% increase for every 1 mmHg) and accelerated sharply beyond 160 mmHg.
- Age-Dose Interaction: The effect of age on bleeding depended on TNK dose. Whereas each additional year of age increased the odds of ICH by 1% at a 30 mg dose this risk rose by nearly 7% at a 50 mg dose.
To translate these findings into clinical practice, the authors developed a risk prediction model based on these five variables. This tool has the potential to help clinicians calculate an individual patient’s likelihood of brain bleeding at the fist point of care prior to TNK therapy. The model held up in internal validation but has not yet been tested in an independent patient group.
Ultimately, these findings suggest that lowering TNK doses in older adults and actively managing blood pressure prior to administration may help reduce bleeding risks, providing valuable insights to inform future treatment guidelines.
